JP2023530154A5 - - Google Patents

Info

Publication number
JP2023530154A5
JP2023530154A5 JP2022577503A JP2022577503A JP2023530154A5 JP 2023530154 A5 JP2023530154 A5 JP 2023530154A5 JP 2022577503 A JP2022577503 A JP 2022577503A JP 2022577503 A JP2022577503 A JP 2022577503A JP 2023530154 A5 JP2023530154 A5 JP 2023530154A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
composition according
flexneri
glucose
glycosylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022577503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530154A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/055361 external-priority patent/WO2021255684A1/en
Publication of JP2023530154A publication Critical patent/JP2023530154A/ja
Publication of JP2023530154A5 publication Critical patent/JP2023530154A5/ja
Pending legal-status Critical Current

Links

JP2022577503A 2020-06-18 2021-06-17 赤痢菌4価(Shigella4V)バイオコンジュゲート Pending JP2023530154A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063040844P 2020-06-18 2020-06-18
US63/040,844 2020-06-18
US202063043883P 2020-06-25 2020-06-25
EP20182139 2020-06-25
EP20182138 2020-06-25
EP20182139.4 2020-06-25
US63/043,883 2020-06-25
EP20182138.6 2020-06-25
PCT/IB2021/055361 WO2021255684A1 (en) 2020-06-18 2021-06-17 Shigella-tetravalent (shigella4v) bioconjugate

Publications (2)

Publication Number Publication Date
JP2023530154A JP2023530154A (ja) 2023-07-13
JP2023530154A5 true JP2023530154A5 (cg-RX-API-DMAC7.html) 2024-06-20

Family

ID=76502778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577503A Pending JP2023530154A (ja) 2020-06-18 2021-06-17 赤痢菌4価(Shigella4V)バイオコンジュゲート

Country Status (8)

Country Link
US (1) US20230346902A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168040A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023530154A (cg-RX-API-DMAC7.html)
CN (1) CN115697396A (cg-RX-API-DMAC7.html)
BR (1) BR112022024294A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185719A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022016587A (cg-RX-API-DMAC7.html)
WO (1) WO2021255684A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026087718A1 (en) * 2024-10-23 2026-04-30 Institut Pasteur A multivalent shigella vaccine and methods of making and using thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
ES2535084T3 (es) 2005-05-11 2015-05-05 Eth Zurich Proteínas N-glicosiladas recombinantes procedentes de células procariotas
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
US9238830B2 (en) 2006-12-13 2016-01-19 The Governors Of The University Of Alberta Methods and systems for O-glycosylating proteins
SI2257307T1 (sl) 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
CN101569744A (zh) * 2009-01-20 2009-11-04 张鑫 一种细菌性痢疾多价疫苗
NO2501406T3 (cg-RX-API-DMAC7.html) 2009-11-19 2018-05-19
KR20150068998A (ko) * 2012-10-12 2015-06-22 글리코박신 아게 숙주 세포 변형 방법
EP2917351B1 (en) * 2012-11-07 2018-12-19 GlaxoSmithKline Biologicals S.A. Production of recombinant vaccine in e. coli by enzymatic conjugation
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
CN106659799B (zh) * 2014-07-25 2020-07-17 碧奥辛斯有限责任公司 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
CN114796472A (zh) * 2015-06-16 2022-07-29 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition

Similar Documents

Publication Publication Date Title
JP7494276B2 (ja) 非天然アミノ酸とのポリペプチド抗原接合体
CN106535927B (zh) 新颖多糖及其用途
TWI751513B (zh) E. coli O-抗原多醣生物結合物、其製備方法及其使用方法
JP7589164B2 (ja) 大腸菌o抗原多糖のバイオコンジュゲートを製造する方法、その組成物およびその使用方法
CN102482646B (zh) 幽门螺杆菌脂多糖外部核心表位
CN115803087A (zh) 多价疫苗组合物及其用途
US12290563B2 (en) Production of E. coli 018 bioconjugates
Altman et al. Design and immunological properties of Helicobacter pylori glycoconjugates based on a truncated lipopolysaccharide lacking Lewis antigen and comprising an α-1, 6-glucan chain
US20230346902A1 (en) Shigella-Tetravalent (Shigella4V) Bioconjugate
HK40129496A (en) Polypeptide-antigen conjugates with non-natural amino acids
JP2025535072A (ja) モラクセラ科o結合型オリゴ糖転移酵素、糖鎖付加断片、及びそれらの使用
HK40015413B (en) Polypeptide-antigen conjugates with non-natural amino acids
HK40015413A (en) Polypeptide-antigen conjugates with non-natural amino acids